



Ovarian Epithelial Tumors, Do Not Get Stumped
The International Academy of Pathology
Hong Kong Division

Anaís Malpica, M.D.

Professor

Department of Pathology




Making Cancer History®

No conflicts of interest

High Grade Serous Ca, Issues

- Using the architecture and not paying attention to the degree of atypia to assign the grade
- Tumor heterogeneity
- A wide variety of patterns and appearances
- Recurrence has a different histotype
 - Carcinosarcoma -- undersampling vs. lack of recognition vs. dedifferentiation
 - Sarcoma –undersampling vs. lack of recognition vs. dedifferentiation
 - Neuroendocrine Ca lack of recognition

Pathologist does not follow diagnostic criteria




High grade serous Ca, interpreted as low grade


Low grade serous Ca, interpreted as high grade

Serous Carcinoma, Tumor Heterogeneity, Low Grade and High Grade


- Uncommon
- Synchronous or metachronous phenomenon
- A problem when dealing with limited tissue





Serous Carcinoma, Tumor Heterogeneity, Low Grade and High Grade




High Grade Serous Ca, Papillary Pattern, Mimicking a Serous Borderline Tumor with a Micropapillary Pattern









High Grade Serous Ca, Broad Base Papillae (TCC Pattern) and Papillae with Prominent Vessels





High Grade Serous Ca

Solid pattern Spindle cells












High Grade Serous Ca, Follicles, and Colloid-like Material







High Grade Serous Ca




WT-1 +




Adenosquamoid appearance





High Grade Serous Ca, vacuoles







Neuroendocrine Ca and HGSCa









High Grade Serous Ca, post-treatment




High Grade Serous Ca, post-treatment






High Grade Serous Ca, post-treatment



High Grade Serous Ca, post-treatment aberrant p53 (over expression)


High Grade Serous Ca, post-treatment aberrant p53 (over expression)





p16 block staining pattern

High Ki-67 proliferative index


High Grade Serous Ca, core biopsy










High Grade Serous Ca, core biopsy, deeper section









High Grade Serous Ca, core biopsy







p53 null p16 +


Extrauterine High Grade Serous Carcinoma: p53




Wild-type, < 10% of cases









Nuclear overexpression

Null phenotype

Cytoplasmic overexpression

Attention to a Histotyping Pitfall

Endometrioid Ca with mucinous metaplasia


Should not be designated as mucinous Ca


or seromucinous Ca


Seromucinous Ca arising in a seromucinous borderline tumor is a RARE TUMOR

Papillae Lined by Endocervical-Type Epithelium and Stromal Edema


Papillae Lined by Endocervical-Type Epithelium with Squamoid Areas







Endometrioid Carcinoma with Mucinous Metaplasia



1233 Primary Ovarian Endometrioid Adenocarcinoma With Mucinous Metaplasia (POEM): An Under Recognized Entity With Therapeutic Implications

Charanjeet Singh, Preetha Ramalingam, Elizabeth Euscher, Anais Malpica. University of Texas MD Anderson Cancer Center, Houston, TX.

Background: Mucinous metaplasia is well-recognized in endometrial endometrioid adenocarcinoma (EEC), but not in ovarian endometrioid carcinoma. Misdiagnosis has therapeautic implications as ovarian mucinous carcinomas are increasingly being treated with chemotherapy regimens used for colonic tumors. In this study, we present our experience with cases of POEM and highlight the pathologic features that can lead to their correct identification.

Design: 37 cases of POEM with available slides and follow up (f/u) from 2000-2014 were reviewed. Pathologic parameters recorded included laterality, tumor size, initial diagnosis, presence of endometriosis, type of borderline component, amount of mucinous metaplasia, other endometrioid adenocarcinoma associated cytologic changes, tumor grade, presence and pattern of invasion, tumor stage and concurrent endometrial pathology. Clinical parameters including patient age, adjuvant chemotherapy and f/u were recorded.

Results: Patients' (pts) age ranged from 26-71yrs (mean, 51). Tumor laterality: 18 left, 10 right, 9 bilateral. Tumor size ranged from 2.5 to 48 cm(mean 12.7). All 32 consult cases, reclassified as POEM, were initially diagnosed as:22 mucinous carcinoma/adenocarcinoma, NOS (59%), 10 mucinous borderline tumor with foci suspicious for carcinoma (27%). According to the tumor grade, cases were distributed as:grades 1 and 2 (32 cases), grade 3 (5 cases). The percentage of mucinous metaplasia in POEM ranged from 5-95% (mean 47%). Squamous metaplasia was seen in 17 cases, while 18 and 6 cases had secretory and clear changes, respectively. 26 cases showed only expansile invasion (EI), 9 EI and infiltrative invasion and 2 only infiltrative invasion. The histology of the borderline component was endocervical (12), endometrioid (3) or mixed (21).18 cases had endometriosis. Tumor stage of POEMs: 23 Stage-I, 3 Stage-II, 3 Stage-III and 2 Stage-IV.16 cases had concurrent grade 1 EEC (5), grade 2 EEC (9) or complex atypical hyperplasia (2). 20 pts. received adjuvant chemotherapy. F/u ranged from 1-96 mos (mean 11). At most recent f/u, 28 pts are alive without evidence of disease while 4 died of disease and 5 died of other causes.


Conclusions: POEMs are under recognized and due to mucinous metaplasia can be misdiagnosed as ovarian mucinous carcinomas, resulting in incorrect therapy.

These tumors are frequently associated with a borderline tumor-either mixed or endocervical type (89%), endometriosis (48%) and EEC (43%).


Presence of squamous metaplasia, secretory change or a nonintestinal type borderline tumor can facilitate the correct diagnosis of POEM.

• 37 cases


Association with:





- 71% expansile pattern of invasion
- 59% initially diagnosed as mucinous carcinoma



Seromucinous Carcinoma Arising in a Seromucinous Borderline is a Rare Tumor









Endometrioid Ca, high grade, pilomatrix-like


Endometrioid Ca, high grade, pilomatrix-like





Endometrioid Ca Mimicking Serous Ca




Endometrioid Ca Mimicking Serous Ca








Endometrioid Ca Mimicking Serous Ca








p53, wild type


Endometrioid Ca Mimicking Serous Ca




p53, wild type

WT-1 +


Endometrioid Ca and Poorly Differentiated SCa







p40

Endometrioid Ca with a Transitional Cell Pattern







Clear Cell Carcinoma with Squamous Differentiation




Clear Cell Carcinoma with Abundant Mucin or Signet-Ring Cells









Clear Cell Carcinoma with Transitional Cell Pattern





p504s WT-1

Clear Cell Carcinoma with Sarcomatoid Features












Clear Cell Ca, core bx




Clear Cell Carcinoma and Yolk Sac Tumor





Clear Cell Carcinoma and Yolk Sac Tumor






Mesonephric-like Ca











GATA-3 and/or TTF1 +

Mesonephric-like Ca













ER and PR -SF-1, calretinin and inhibin -

Mesonephric-like Ca











TTF-1+



ER/PR rare cells +



WT-1 -



Extrauterine Mesonephric-like Carcinoma

A Comprehensive Single Institution Study of 33 Cases

Elizabeth D. Euscher, MD,* Mario L. Marques-Piubelli, MD,* Preetha Ramalingam, MD,* Ignacio Wistuba, MD,* Barrett C. Lawson, MD,* Michael Frumovitz, MD,† and Anais Malpica, MD*

(Am J Surg Pathol 2023;00:000-000)

Pts' age: 37-74 yrs (median, 59 yrs)

Advanced stage disease (FIGO III/IV), 13

Sarcomatous differentiation, 2

Associations:

endometriosis (63%)

borderline tumor (21%)

part of a mixed Ca (42%)


Misclassified, 42%

Molecular Findings: Kras>>>Tp53, SPOP, PIK3CA

Metastasis: liver, lung, peritoneum


More aggressive than low grade endometrioid Ca


Malignant Brenner Tumor




Molecular Findings


- PIK3CA mutations
- *MDM2* amplification








Malignant Brenner Tumor




Malignant Brenner Tumor


Brenner Tumor

Borderline Brenner Tumor





Malignant Brenner Tumor







Twilight Epiphany

Live Oak Friends Meeting House